An investigation into colorectal cancer in Scotland

  • Research type

    Research Study

  • Full title

    An investigation into Colorectal Cancer in Scotland

  • IRAS ID

    346767

  • Contact name

    Allan Golder

  • Contact email

    allan.golder@glasgow.ac.uk

  • Sponsor organisation

    NHS GG&C Research and Innovation (R&I)

  • Duration of Study in the UK

    5 years, 0 months, 1 days

  • Research summary

    Colorectal cancer is highly prevalent and a leading cause of morbidity and mortality within Scotland. Outcomes in Scotland have been reported to be poor in comparison to other similar Western Nations.

    This research aims to investigate the changes in colorectal cancer presentations/treatment/outcomes over the last 50 years. This includes the introduction of screening, surgical specialisation, a move to minimally invasive and robotic surgery. It will provide an insight into the longitudinal changes in a number of factors including disease stage at presentation, mode of presentation (elective/emergency), age at presentation and outcomes.

    This research will examine a number of areas within colorectal cancer including route to diagnosis (if not screening, why not?), the differences between younger onset (age <50) and "standard" onset colorectal cancer and outcomes within a number of groups including conservatively (non-operatively) managed cancers. Of particular interest is detailed analysis of socioeconomic deprivation on the presentation, treatment and outcomes of patients with colorectal cancer.

    This project will examine factors associated with deprivation in patients with bowel cancer across the whole of Scotland including income, education, ethnic minority status, engagement with screening and lifestyle factors to determine how these factors influence the presentation and disease biology of bowel cancer and subsequent treatment and outcomes. The inclusion of the pre-, peri- and post-COVID 19 Pandemic populations will allow us to determine the impact of COVID-19 on these patients.

    Our results will help to guide future strategies to improve both bowel cancer screening and cancer care for patients with bowel cancer. This has the potential to improve outcomes for all patients with bowel cancer however offers the greatest potential benefits to the most deprived people in our society.

  • REC name

    Yorkshire & The Humber - Leeds East Research Ethics Committee

  • REC reference

    25/YH/0197

  • Date of REC Opinion

    17 Nov 2025

  • REC opinion

    Further Information Favourable Opinion